Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material Patents (Class 424/130.1)
  • Patent number: 10663462
    Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: May 26, 2020
    Inventors: Andreas Pfuetzner, Thomas Forst
  • Patent number: 10654925
    Abstract: The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: May 19, 2020
    Assignee: CTS Biopharma LLC
    Inventors: James W. Larrick, John M. Wages, Andrew R. Mendelsohn, Vikram Sharma, Bo Yu
  • Patent number: 10647672
    Abstract: Compounds with activity as modulators of cell adhesion are disclosed. The compounds are derivatives of piperidin-4-amine. In some embodiments, a compound can be linked to a targeting agent, a pharmaceutically active substance and/or a support material. Methods for enhancing or inhibiting classical cadherin-mediated functions are also disclosed. The compounds can be used for the treatment or prevention of a variety of diseases including cancer. Compositions and devices, including skin patches comprising a compound are also disclosed. In addition, methods of synthesis of the compounds are provided.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: May 12, 2020
    Assignee: Zonula, Inc.
    Inventor: Orest William Blaschuk
  • Patent number: 10646565
    Abstract: Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 12, 2020
    Assignee: AFFIRIS AG
    Inventors: Markus Mandler, Achim Schneeberger, Frank Mattner, Walter Schmidt
  • Patent number: 10646569
    Abstract: The present disclosure, among other things, provides low-viscosity, high concentration therapeutic protein agent formulations.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 12, 2020
    Assignee: Bhami's Research Laboratory, Pvt. Ltd.
    Inventor: Bhami Shenoy
  • Patent number: 10633431
    Abstract: The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis C virus, and specifically to antibodies against the hepatitis C virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology. Proposed is the use of fully human monoclonal antibodies—RYB1, RYB2 and RYB3—and of a composition based thereon for the prevention and treatment of hepatitis C. Said antibodies are produced by cultivation using hybrid BIONA-RYB1, BIONA-RYB2 and BIONA-RYB3. The effectiveness of the antibodies is due to said antibodies binding epitopes, namely Ep1, Ep2 and Ep3 of E2 protein of the hepatitis C viral envelope, respectively. The present invention has demonstrated a neutralizing activity of the antibodies in a model system of infection of human cells in a culture. It has been shown that use of the claimed group of inventions provides for more reliable antibody binding of the hepatitis C virus.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: April 28, 2020
    Inventors: Tatiana Nikolaevna Vlasik, Armen Sergeevich Sadgyan, Igor Nikolaevich Rybalkin, Alexandr Yasenovich Shevelev
  • Patent number: 10631743
    Abstract: A guided meditation system, such as a virtual reality (VR) guided meditation system, provides biofeedback. Wearable devices (e.g., fitness trackers) record information about a physiological state of a user (e.g., heart rate, blood pressure, sleep, and activity data). Performing guided meditation exercises may help users improve their physiological state (e.g., by decreasing a user's heart rate). The VR guided meditation system automatically retrieves physiological state information from wearable devices or third party applications before and/or after a user performs guided meditation exercises. Based on the retrieved information, the VR guided meditation system provides biofeedback related to effects or potential correlations between an exercise and the user's physiological state. In particular, the biofeedback indicates a certain type of meditation, certain VR environment location, or certain meditation duration that is likely to improve the user's physiological state.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: April 28, 2020
    Assignee: THE STAYWELL COMPANY, LLC
    Inventors: Alex Jeffrey Goldberg, Aaron Serling Goldberg
  • Patent number: 10633441
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 28, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • Patent number: 10618978
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 14, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
  • Patent number: 10617718
    Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: April 14, 2020
    Assignee: Axial Biotherapeutics, Inc.
    Inventors: Anthony Stewart Campbell, David H. Donabedian
  • Patent number: 10619219
    Abstract: The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., endonuclease) substrates, and probes and compositions useful in detection assays.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: April 14, 2020
    Assignee: University of Iowa Research Foundation
    Inventors: James O. McNamara, Katie R. Flenker, Hyeon Kim, Alexander R. Horswill, Frank J. Hernandez, Mark Behlke, Lingyan Huang, Richard Owczarzy, Elliot Burghardt, Karen Clark
  • Patent number: 10610578
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 7, 2020
    Assignee: IMMODULON THERAPEUTICS LIMITED
    Inventors: Charles Akle, John Grange, Kevin Bilyard
  • Patent number: 10604563
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 31, 2020
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
  • Patent number: 10604576
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • Patent number: 10603350
    Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: March 31, 2020
    Assignee: HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
    Inventors: Xiaofang Luo, Zuodong Qin, Fulin He, Xiaoping Ouyang, Zhizhang Li, Changjian Li, Qianrui Peng, Zhesheng Chen
  • Patent number: 10604759
    Abstract: Methods and compositions capable of modulating activity of TLX (NR2E1), a nuclear receptor essential for neural stem cell self-renewal are provided. The modulations may comprise downregulating TLX expression and/or modulating TET3. In addition, methods of delivering shRNAs using dendrimer nanoparticles into glioblastoma stem cells are provided. The methods and compositions are useful for treating and preventing the progression of brain cancer, e.g. glioblastoma.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 31, 2020
    Assignee: CITY OF HOPE
    Inventors: Yanhong Shi, Qi Cui, Su Yang
  • Patent number: 10597457
    Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 24, 2020
    Assignee: PHARMABCINE INC.
    Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
  • Patent number: 10597461
    Abstract: Provided are antibodies that specifically bind to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Also provided are compositions including these antibodies, as well as polynucleotides, vectors, host cells, and methods useful for production thereof. Further provided are methods and kits for treating or preventing cancer in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, optionally in combination with another anti-cancer agent. Still further provided are methods and kits for treating or preventing gastrointestinal disease in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 24, 2020
    Assignee: B & H Biotechnologies, LLC
    Inventor: Huiru Wang
  • Patent number: 10598655
    Abstract: Disclosed are methods of detecting the presence of Loa loa in a biological sample using one or more antigens, each having a different amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20. Related compositions, specific binding partners, and test kits are also disclosed.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 24, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas B. Nutman, Sasisekhar Bennuru, Papa Makhktar Drame
  • Patent number: 10596246
    Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 24, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventors: Beatrice Maria Arico, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli
  • Patent number: 10590193
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • Patent number: 10583171
    Abstract: The present invention relates to an N-Methyl-D-aspartate (NMDA) receptor antagonist, for use in the treatment of diseases associated with angiogenesis such as tumor angiogenesis, ocular neovascular disease, Age-related macular degeneration (AMD).
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: March 10, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Sud
    Inventors: Sylvia Cohen-Kaminsky, Sebastien Dumas, Gilles Bru-Mercier
  • Patent number: 10583190
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 10, 2020
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Patent number: 10584181
    Abstract: Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: March 10, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Richard L. Vandlen
  • Patent number: 10585097
    Abstract: Herein is reported a method for determining bacterial endotoxin at low concentrations in a sample of an antibody (that has been produced using bacterial cells) comprising the following steps in the following order: i) adding magnesium ions to the sample, ii) diluting the sample, iii) dialyzing the sample having a pH-value of 5.7-8.0 against an endotoxin-free aqueous solution, and iv) determining bacterial endotoxin in the sample using a bacterial endotoxin test, particularly the limulus amoebocyte lysate assay.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: March 10, 2020
    Assignees: Forschungszentrum Borstel Leibniz Lungerzentrum, Hoffmann-La Roche Inc.
    Inventors: Christian Alexander, Sven Deutschmann, Pierre Lang, Friedrich Von Wintzingerode, Ulrich Zaehringer
  • Patent number: 10584171
    Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: March 10, 2020
    Assignee: Henlix Biotech Co., Ltd.
    Inventors: Wei-Dong Jiang, Pei-Hua Lin
  • Patent number: 10584170
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: March 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10584347
    Abstract: The present invention provides recombinant host cells that produce proteins or therapeutic proteins, and nucleic acid constructs for producing the cells. The cells have nucleic acid constructs that encode a heterologous protein, for example an antibody. The nucleic acid constructs also can have a functional signal sequence that directs the secretion of the protein from the cell. The signal sequence can be any functional signal sequence, and various signal sequences are disclosed herein. The invention also provides methods of producing the proteins.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: March 10, 2020
    Assignee: Conagen Inc.
    Inventors: Nicky C. Caiazza, Jun Urano, Maung N. Win, Kent S. Boles
  • Patent number: 10577423
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: March 3, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10570202
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 25, 2020
    Assignees: Pfizer Inc., Merck Sharpe & Dohme Corp.
    Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • Patent number: 10568962
    Abstract: A method of cancer hyperthermia therapy includes placing a device including an exogenously-excitable polymeric material at a cancer hyperthermia therapy site of a patient. The method also includes supplying an exogenous energy to the device such that the exogenous energy excites the exogenously-excitable polymeric material at the cancer hyperthermia therapy site to heat the cancer hyperthermia therapy site to a hyperthermia temperature. A method of preparing a polymeric material includes combining an alcohol monomer, a seed of the polymeric material, and an aqueous liquid in a vessel. The method also includes adding an acid monomer to the vessel and supplying an exogenous energy to the vessel. The polymeric material is exogenously excited by the exogenous energy to heat the polymeric material. The method further includes removing water from the vessel and producing the polymeric material, which is a polyester, in the vessel.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: February 25, 2020
    Assignee: THE SECANT GROUP, LLC
    Inventors: Peter D. Gabriele, Jared Ely, Jeremy J. Harris
  • Patent number: 10561639
    Abstract: A composition for the treatment of cancerous cells. The composition including a combination of at least one tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor. This combinatorial approach involves direct inhibition of the thioredoxin molecule (and not the enzyme of Trx reductase).
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: February 18, 2020
    Assignee: University of Huddersfield
    Inventor: Nikolaos Georgopoulos
  • Patent number: 10562976
    Abstract: Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: February 18, 2020
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Wei-Ying Kuo, Hung-Ju Hsu, Hong-Sen Chen, Yu-Chi Chou, Yueh-Liang Tsou, Hung-Pin Peng, Jhih-Wei Jian, Chung-Ming Yu, Yi-Kai Chiu, Ing-Chein Chen, Chao-Ping Tung, Michael Hsiao, Hwei-Jiung Wang
  • Patent number: 10551391
    Abstract: Mycolic acid antigen containing liposomes, and an electrode immobilised antigens of tuberculous mycobacterial origin are produced. A diagnostic sample from a human suspected of having tuberculosis is diluted and divided into first and second samples. A control sample comprising the first sample and a redox probe is exposed to the liposomes. A test sample comprising the second sample and a redox probe is exposed to liposomes not containing mycolic acid antigens. The control sample is contacted with the immobilised antigens to allow antibodies therein to bind to the antigens. The test sample is contacted with the immobilised antigens to allow any antibodies therein to bind to the antigens. The degree of binding in the samples is compared by electrochemical impedance spectroscopy. Any observed lesser binding by the control sample is an indicator of antibodies to the antigens in the diagnostic sample, indicating tuberculosis in the human.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: February 4, 2020
    Assignee: University of Pretoria
    Inventors: Jan Adrianus Verschoor, Carl Baumeister
  • Patent number: 10548979
    Abstract: The invention includes light-activated compositions and methods that are useful for promoting cell death or growth. In certain embodiments, the compositions comprise quantum dots (QD).
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 4, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Prashant Nagpal, Anushree Chatterjee, Colleen Courtney, Samuel Martin Goodman
  • Patent number: 10538590
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: January 21, 2020
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 10538588
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: January 21, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • Patent number: 10517830
    Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Prothena Biosciences Limited
    Inventors: Patrick Garidel, Isaac Craig Henderson, Pamela Klein
  • Patent number: 10519235
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: December 31, 2019
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
  • Patent number: 10520508
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 31, 2019
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Patent number: 10517875
    Abstract: Materials and methods for treating potentially chemoresistant tumors (e.g., using DNA-PKcs inhibitors and anti-B7-H1 antibodies) are provided herein.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: December 31, 2019
    Assignee: Mayo Foundation for Medical Engineering and Research
    Inventor: Haidong Dong
  • Patent number: 10517945
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 31, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Joerg Benz, Ulrich Brinkmann, Stefan Dengl, Sebastian Dziadek, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann
  • Patent number: 10512674
    Abstract: A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: December 24, 2019
    Inventors: Michael Pikal, Serguei Tchessalov, Erik Bjornson, Feroz Jameel, Marc Besman
  • Patent number: 10513699
    Abstract: A method of preparing a conditionally active biologic protein by selecting a wild-type biologic protein, evolving the DNA which encodes the wild-type biologic protein using one or more evolutionary techniques to create mutant DNAs, expressing the mutant DNAs in a eukaryotic cell production host to obtain a mutant protein, subjecting the mutant protein and the wild-type protein to an assay under a normal physiological condition and to an assay under an aberrant condition, selecting a conditionally active mutant protein which exhibits at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type protein, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type protein; and producing the conditionally active biologic protein in the same eukaryotic cell production host used in the expression step.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 24, 2019
    Assignee: BioAtla, LLC
    Inventor: Jay M. Short
  • Patent number: 10508200
    Abstract: A composition including a) 55-98.9 wt % of at least one type of triblock copolymer (A) of formula (1) R—B-A-B—R??(1) b) 0.1-15 wt % of at least one surfactant (B) and c) 1-30 wt % of water, wherein A is a hydrophilic block having a number average molecular weight (Mn) of 100-1,000 Da, B is a hydrophobic block made from monomers having at least a monomer B1 and a monomer B2, wherein B1 and B2 have the largest weight contents in the hydrophobic block and B1 has a lower molecular weight than B2, wherein R is an end group which is H or a C1-C30 organic moiety, wherein the composition is fluid in a temperature range of 0° C. to 37° C., wherein the weight % are relative to the sum of a), b) and c), and wherein the sum of components a), b) and c) is at least 80 wt % of the entire composition, preferably at least 90 wt %; to the use of the composition and to pharmaceutical compositions having said composition and an active pharmaceutical ingredient.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: December 17, 2019
    Assignee: INGELL TECHNOLOGIES HOLDING B.V.
    Inventors: Ronald Meijboom, Paul Marcel Van Midwoud, Maarten Van Dijk, Theodorus Adrianus Cornelius Flipsen, Esther De Boef
  • Patent number: 10501780
    Abstract: Sample preparation processes for in situ RNA or DNA analysis, methods and compositions therefor are provided. Processes provided herein allow DNA or RNA analysis to be carried out in the same tube or on an aliquot of the prepared sample without centrifugation or extraction. The preparation process can be carried out at room temperature in as little as seven minutes and is amenable to high throughput processing using manual or robotic platforms.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 10, 2019
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventors: Richard A. Fekete, Annalee Nguyen
  • Patent number: 10502739
    Abstract: Antibiotics (Abx) are the world's most misused drugs. Antibiotics misuse occurs when the drug is administered in case of a non-bacterial infection (such as a viral infection) for which it is ineffective. Overall, it is estimated that 40-70% of the worldwide Abx courses are mis-prescribed. The financial and health consequences of Abx over-prescription include the direct cost of the drugs, as well as the indirect costs of their side effects, which are estimated at >$15 billion annually. Furthermore, over-prescription directly causes the emergence of Abx-resistant strains of bacteria, which are recognized as one of the major threats to public health today. This generates an immediate need for reliable diagnostics to assist physicians in correct Abx prescription, especially at the point-of-care (POC) where most Abx are prescribed. Accordingly, some aspects of the present invention provide methods using biomarkers for rapidly detecting the source of infection and administrating the appropriate treatment.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 10, 2019
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Kfir Oved, Eran Eden, Ilan Ifergan
  • Patent number: 10501544
    Abstract: Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides, compositions, and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: December 10, 2019
    Assignee: Spring BioScience Corporation
    Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
  • Patent number: 10501534
    Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 10, 2019
    Assignees: Leidos, Inc., The U.S. of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
  • Patent number: 10493151
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: December 3, 2019
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy